- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Good
|
- 10-K Annual report
- 10.1.5 Form of 2007 Restricted Stock Award Agreement
- 10.4 Form of Indemnification Agreement
- 10.9.6 Sixth Amendment to Lease Agreement
- 10.10 Consent to Assignment of Lease Agreement
- 10.11 First Amendment to Consent of Sublease Agreement
- 10.14 Side Letter
- 10.15 Antigenics Consent Agreement
- 10.18.1 Amendment No. 1,2,3,5,6 and 7 to Exclusive License Agreement with Aronex Pharm.
- 10.19 Amended & Restated License Agreement
- 10.28 2004 Executive Incentive Plan
- 23 Consent of KPMG LLP
- 31.1 Certification of CEO Pursuant to Section 302
- 31.2 Certification of CFO Pursuant to Section 302
- 32.1 Certification of CEO & CFO Pursuant to Section 906
Exhibit 23
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Antigenics Inc.:
We consent to the incorporation by reference in the registration statements on Form S-8 (Nos. 333-40440, 333-40442, 333-50434, 333-69580, 333-106072, and 333-115984) and on Form S-3 (Nos. 333-118171, 333-149116, and 333-69582) of Antigenics Inc. of our reports dated March 14, 2008, with respect to the consolidated balance sheets of Antigenics Inc. and subsidiaries as of December 31, 2007 and 2006, and the related consolidated statements of operations, stockholders’ (deficit) equity and comprehensive loss, and cash flows for each of the years in the three-year period ended December 31, 2007, and the effectiveness of internal control over financial reporting as of December 31, 2007, which reports appear in the December 31, 2007 annual report on Form 10-K of Antigenics Inc.
Our report dated March 14, 2008 on the consolidated financial statements refers to the adoption of Statement of Financial Accounting Standards No. 123R,Share-Based Payment, effective January 1, 2006.
/s/ KPMG LLP
Boston, Massachusetts
March 14, 2008